Table of Contents Author Guidelines Submit a Manuscript
Letter to the Editor
Canadian Journal of Gastroenterology and Hepatology
Volume 2016 (2016), Article ID 5234969, 11 pages
http://dx.doi.org/10.1155/2016/5234969
Review Article

Evaluation of Antiviral Therapy Performed after Curative Therapy in Patients with HBV-Related Hepatocellular Carcinoma: An Updated Meta-Analysis

Department of Hepatobiliary Surgery, The First Affiliated Hospital of Anhui Medical University, Hefei 230032, China

Received 22 July 2015; Accepted 1 September 2015

Copyright © 2016 Peng Yuan et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. A. I. Gomaa, S. A. Khan, M. B. Toledano, I. Waked, and S. D. Taylor-Robinson, “Hepatocellular carcinoma: epidemiology, risk factors and pathogenesis,” World Journal of Gastroenterology, vol. 14, no. 27, pp. 4300–4308, 2008. View at Publisher · View at Google Scholar · View at Scopus
  2. J. M. Llovet, A. Burroughs, and J. Bruix, “Hepatocellular carcinoma,” The Lancet, vol. 362, no. 9399, pp. 1907–1917, 2003. View at Publisher · View at Google Scholar · View at Scopus
  3. H. L.-Y. Chan and J. J.-Y. Sung, “Hepatocellular carcinoma and hepatitis B virus,” Seminars in Liver Disease, vol. 26, no. 2, pp. 153–161, 2006. View at Publisher · View at Google Scholar · View at Scopus
  4. C. Chong, G. Wong, V. Wong et al., “Antiviral therapy improves post-hepatectomy survival in patients with hepatitis B virus-related hepatocellular carcinoma: a prospective-retrospective study,” Alimentary Pharmacology and Therapeutics, vol. 41, no. 2, pp. 199–208, 2015. View at Publisher · View at Google Scholar · View at Scopus
  5. J. Wong, K. F. Lee, P. S. F. Lee et al., “Radiofrequency ablation for 110 malignant liver tumours: preliminary results on percutaneous and surgical approaches,” Asian Journal of Surgery, vol. 32, no. 1, pp. 13–20, 2009. View at Publisher · View at Google Scholar · View at Scopus
  6. T. Toyama, N. Hiramatsu, T. Yakushijin et al., “A new prognostic system for hepatocellular carcinoma including recurrent cases: a study of 861 patients in a single institution,” Journal of Clinical Gastroenterology, vol. 42, no. 3, pp. 317–322, 2008. View at Publisher · View at Google Scholar · View at Scopus
  7. J. M. Llovet, M. Schwartz, and V. Mazzaferro, “Resection and liver transplantation for hepatocellular carcinoma,” Seminars in Liver Diseases, vol. 25, no. 2, pp. 181–200, 2005. View at Publisher · View at Google Scholar
  8. G. Huang, E. C. H. Lai, W. Y. Lau et al., “Posthepatectomy HBV reactivation in hepatitis B-Related hepatocellular carcinoma influences postoperative survival in patients with preoperative low HBV-DNA levels,” Annals of Surgery, vol. 257, no. 3, pp. 490–505, 2013. View at Publisher · View at Google Scholar · View at Scopus
  9. H.-C. Sun, W. Zhang, L.-X. Qin et al., “Positive serum hepatitis B e antigen is associated with higher risk of early recurrence and poorer survival in patients after curative resection of hepatitis B-related hepatocellular carcinoma,” Journal of Hepatology, vol. 47, no. 5, pp. 684–690, 2007. View at Publisher · View at Google Scholar · View at Scopus
  10. I. F. N. Hung, R. T. P. Poon, C.-L. Lai, J. Fung, S.-T. Fan, and M.-F. Yuen, “Recurrence of hepatitis b-related hepatocellular carcinoma is associated with high viral load at the time of resection,” American Journal of Gastroenterology, vol. 103, no. 7, pp. 1663–1673, 2008. View at Publisher · View at Google Scholar · View at Scopus
  11. Y. Hoshida, “Risk of recurrence in hepatitis B-related hepatocellular carcinoma: impact of viral load in late recurrence,” Journal of Hepatology, vol. 51, no. 5, pp. 842–844, 2009. View at Publisher · View at Google Scholar · View at Scopus
  12. H. J. An, J. W. Jang, S. H. Bae et al., “Sustained low hepatitis B viral load predicts good outcome after curative resection in patients with hepatocellular carcinoma,” Journal of Gastroenterology and Hepatology, vol. 25, no. 12, pp. 1876–1882, 2010. View at Publisher · View at Google Scholar · View at Scopus
  13. Y. Zhou, Z. Zhang, Y. Zhao, L. Wu, and B. Li, “Antiviral therapy decreases recurrence of hepatitis B virus-related hepatocellular carcinoma after curative resection: a meta-analysis,” World Journal of Surgery, vol. 38, no. 9, pp. 2395–2402, 2014. View at Publisher · View at Google Scholar · View at Scopus
  14. Y. Ke, L. Wang, L.-Q. Li, and J.-H. Zhong, “Nucleos(t)ide analogues to treat hepatitis B virus-related hepatocellular carcinoma after radical resection,” World Journal of Hepatology, vol. 6, no. 9, pp. 652–659, 2014. View at Publisher · View at Google Scholar · View at Scopus
  15. J. S.-W. Wong, G. L.-H. Wong, K. K.-F. Tsoi et al., “Meta-analysis: the efficacy of anti-viral therapy in prevention of recurrence after curative treatment of chronic hepatitis B-related hepatocellular carcinoma,” Alimentary Pharmacology and Therapeutics, vol. 33, no. 10, pp. 1104–1112, 2011. View at Publisher · View at Google Scholar · View at Scopus
  16. N. Li, E. C. H. Lai, J. Shi et al., “A comparative study of antiviral therapy after resection of hepatocellular carcinoma in the immune-active phase of hepatitis B virus infection,” Annals of Surgical Oncology, vol. 17, no. 1, pp. 179–185, 2010. View at Publisher · View at Google Scholar · View at Scopus
  17. S. Kubo, H. Tanaka, S. Takemura et al., “Effects of lamivudine on outcome after liver resection for hepatocellular carcinoma in patients with active replication of hepatitis B virus,” Hepatology Research, vol. 37, no. 2, pp. 94–100, 2007. View at Publisher · View at Google Scholar · View at Scopus
  18. C.-Y. Piao, S.-I. Fujioka, Y. Iwasaki et al., “Lamivudine treatment in patients with HBV-related hepatocellular carcinoma—using an untreated, matched control cohort,” Acta Medica Okayama, vol. 59, no. 5, pp. 217–224, 2005. View at Google Scholar · View at Scopus
  19. G. Huang, W. Y. Lau, Z.-G. Wang et al., “Antiviral therapy improves postoperative survival in patients with hepatocellular carcinoma: a randomized controlled trial,” Annals of Surgery, vol. 261, no. 1, pp. 56–66, 2015. View at Publisher · View at Google Scholar · View at Scopus
  20. J. Yin, N. Li, Y. Han et al., “Effect of antiviral treatment with nucleotide/nucleoside analogs on postoperative prognosis of hepatitis B virus-related hepatocellular carcinoma: a two-stage longitudinal clinical study,” Journal of Clinical Oncology, vol. 31, no. 29, pp. 3647–3655, 2013. View at Publisher · View at Google Scholar
  21. M. Koda, T. Nagahara, T. Matono et al., “Nucleotide analogs for patients with HBV-related hepatocellular carcinoma increase the survival rate through improved liver function,” Internal Medicine, vol. 48, no. 1, pp. 11–17, 2009. View at Publisher · View at Google Scholar · View at Scopus
  22. T. Kuzuya, Y. Katano, T. Kumada et al., “Efficacy of antiviral therapy with lamivudine after initial treatment for hepatitis B virus-related hepatocellular carcinoma,” Journal of Gastroenterology and Hepatology, vol. 22, no. 11, pp. 1929–1935, 2007. View at Publisher · View at Google Scholar · View at Scopus
  23. H. Yoshida, H. Yoshida, E. Goto et al., “Safety and efficacy of lamivudine after radiofrequency ablation in patients with hepatitis B virus-related hepatocellular carcinoma,” Hepatology International, vol. 2, no. 1, pp. 89–94, 2008. View at Publisher · View at Google Scholar · View at Scopus
  24. M. Chuma, S. Hige, T. Kamiyama et al., “The influence of hepatitis B DNA level and antiviral therapy on recurrence after initial curative treatment in patients with hepatocellular carcinoma,” Journal of Gastroenterology, vol. 44, no. 9, pp. 991–999, 2009. View at Publisher · View at Google Scholar · View at Scopus
  25. C.-Y. Wu, Y.-J. Chen, H. J. Ho et al., “Association between nucleoside analogues and risk of hepatitis B virus-related hepatocellular carcinoma recurrence following liver resection,” The Journal of the American Medical Association, vol. 308, no. 18, pp. 1906–1914, 2012. View at Publisher · View at Google Scholar · View at Scopus
  26. H.-W. Hann, R. Coben, D. Brown et al., “A long-term study of the effects of antiviral therapy on survival of patients with HBV-associated hepatocellular carcinoma (HCC) following local tumor ablation,” Cancer Medicine, vol. 3, no. 2, pp. 390–396, 2014. View at Publisher · View at Google Scholar · View at Scopus
  27. Y. Ke, L. Ma, X.-M. You et al., “Antiviral therapy for hepatitis B virus-related hepatocellular carcinoma after radical hepatectomy,” Cancer Biology and Medicine, vol. 10, no. 3, pp. 158–164, 2013. View at Publisher · View at Google Scholar · View at Scopus
  28. Y. Urata, S. Kubo, S. Takemura et al., “Effects of antiviral therapy on long-term outcome after liver resection for hepatitis B virus-related hepatocellular carcinoma,” Journal of Hepato-Biliary-Pancreatic Sciences, vol. 19, no. 6, pp. 685–696, 2012. View at Publisher · View at Google Scholar · View at Scopus
  29. B. W. Xia, Y. C. Zhang, J. Wang, F. H. Ding, and X. D. He, “Efficacy of antiviral therapy with nucleotide/nucleoside analogs after curative treatment for patients with hepatitis B virus-related hepatocellular carcinoma: a systematic review and meta-analysis,” Clinics and Research in Hepatology and Gastroenterology, vol. 39, no. 4, pp. 458–468, 2015. View at Publisher · View at Google Scholar · View at Scopus
  30. P. Sun, X. Dong, X. Cheng, Q. Hu, and Q. Zheng, “Nucleot(s)ide analogues for hepatitis B virus-related hepatocellular carcinoma after curative treatment: a systematic review and meta-analysis,” PLoS ONE, vol. 9, no. 7, Article ID e102761, 2014. View at Publisher · View at Google Scholar · View at Scopus
  31. A. R. Jadad, R. A. Moore, D. Carroll et al., “Assessing the quality of reports of randomized clinical trials: is blinding necessary?” Controlled Clinical Trials, vol. 17, no. 1, pp. 1–12, 1996. View at Publisher · View at Google Scholar · View at Scopus
  32. G. A. Wells, S. B. O'Connell, D. Peterson et al., “The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses,” 2014, http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp.
  33. A. C. Y. Chan, K. S. H. Chok, W. K. Yuen et al., “Impact of antiviral therapy on the survival of patients after major hepatectomy for hepatitis B virus-related hepatocellular carcinoma,” Archives of Surgery, vol. 146, no. 6, pp. 675–681, 2011. View at Publisher · View at Google Scholar · View at Scopus
  34. H. Nishikawa, N. Nishijima, A. Arimoto et al., “Effect of nucleoside analog use in patients with hepatitis B virus-related hepatocellular carcinoma,” Hepatology Research, vol. 44, no. 6, pp. 608–620, 2014. View at Publisher · View at Google Scholar · View at Scopus
  35. J.-C. Wu, Y.-H. Huang, G.-Y. Chau et al., “Risk factors for early and late recurrence in hepatitis B-related hepatocellular carcinoma,” Journal of Hepatology, vol. 51, no. 5, pp. 890–897, 2009. View at Publisher · View at Google Scholar · View at Scopus
  36. S. Kubo, K. Hirohashi, H. Tanaka et al., “Effect of viral status on recurrence after liver resection for patients with hepatitis B virus-related hepatocellular carcinoma,” Cancer, vol. 88, no. 5, pp. 1016–1024, 2000. View at Publisher · View at Google Scholar · View at Scopus
  37. J. L. Dienstag, R. D. Goldin, E. J. Heathcote et al., “Histological outcome during long-term lamivudine therapy,” Gastroenterology, vol. 124, no. 1, pp. 105–117, 2003. View at Publisher · View at Google Scholar · View at Scopus
  38. Y.-F. Liaw, J. J. Y. Sung, W. C. Chow et al., “Lamivudine for patients with chronic hepatitis B and advanced liver disease,” The New England Journal of Medicine, vol. 351, no. 15, pp. 1521–1587, 2004. View at Publisher · View at Google Scholar · View at Scopus
  39. A. Matsumoto, E. Tanaka, A. Rokuhara et al., “Efficacy of lamivudine for preventing hepatocellular carcinoma in chronic hepatitis B: a multicenter retrospective study of 2795 patients,” Hepatology Research, vol. 32, no. 3, pp. 173–184, 2005. View at Publisher · View at Google Scholar · View at Scopus
  40. M.-F. Yuen, W.-K. Seto, D. H.-F. Chow et al., “Long-term lamivudine therapy reduces the risk of long-term complications of chronic hepatitis B infection even in patients without advanced disease,” Antiviral Therapy, vol. 12, no. 8, pp. 1295–1303, 2007. View at Google Scholar · View at Scopus
  41. S. J. Hadziyannis, N. C. Tassopoulos, E. J. Heathcote et al., “Long-term therapy with Adefovir Dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years,” Gastroenterology, vol. 131, no. 6, pp. 1743–1751, 2006. View at Publisher · View at Google Scholar · View at Scopus
  42. E. R. Schiff, S. S. Lee, Y.-C. Chao et al., “Long-term treatment with entecavir induces reversal of advanced fibrosis or cirrhosis in patients with chronic hepatitis B,” Clinical Gastroenterology and Hepatology, vol. 9, no. 3, pp. 274–276, 2011. View at Publisher · View at Google Scholar · View at Scopus
  43. T.-T. Chang, Y.-F. Liaw, S.-S. Wu et al., “Long-term entecavir therapy results in the reversal of fibrosis/cirrhosis and continued histological improvement in patients with chronic hepatitis B,” Hepatology, vol. 52, no. 3, pp. 886–893, 2010. View at Publisher · View at Google Scholar · View at Scopus
  44. C.-C. Yeh, J.-T. Lin, L.-B. Jeng et al., “Nonsteroidal anti-inflammatory drugs are associated with reduced risk of early hepatocellular carcinoma recurrence after curative liver resection: a nationwide cohort study,” Annals of Surgery, vol. 261, no. 3, pp. 521–526, 2015. View at Publisher · View at Google Scholar · View at Scopus